Agonistas de la trombopoyetina como manejo farmacológico de la trombocitopenia inmune primaria

Fecha
2023
Título de la revista
ISSN de la revista
Título del volumen
Editor
Universidad Católica de Cuenca.
Resumen
Primary Immune Thrombocytopenia is an autoimmune hematological disease that is distinguished by having platelets in a number less than 100,000, which causes clinical manifestations in patients such as the presence of ecchymosis, petechiae and even massive hemorrhages that can compromise the patient's life. For its diagnosis, other complementary tests are carried out, since it is a pathology in which there is no standard or specific test to diagnose it, and therefore its diagnosis is made by exclusion; and its treatment is first, second or third line will depend on the number of platelets and the phase of the disease, thrombopoietin agonists standing out over other drugs in the management of chronic or refractory Primary Immune Thrombocytopenia. Describing the pharmacological management of Primary Immune Thrombocytopenia through the administration of thrombopoietin agonists is essential, since through it it will be possible to demonstrate all the patients who benefit from this drug as well as its efficacy and the appearance of adverse effects. It is expected to find that thrombopoietin agonists are effective and safe drugs in the treatment of Primary Immune Thrombocytopenia, although being a safe pharmacological treatment, the risk-benefit must always be assessed in patients suffering from Primary Immune Thrombocytopenia. since through it it will be possible to demonstrate all the patients who benefit from this drug as well as its efficacy and the appearance of adverse effects. It is expected to find that thrombopoietin agonists are effective and safe drugs in the treatment of Primary Immune Thrombocytopenia, although being a safe pharmacological treatment, the risk-benefit must always be assessed in patients suffering from Primary Immune Thrombocytopenia. since through it it will be possible to demonstrate all the patients who benefit from this drug as well as its efficacy and the appearance of adverse effects. It is expected to find that thrombopoietin agonists are effective and safe drugs in the treatment of Primary Immune Thrombocytopenia, although being a safe pharmacological treatment, the risk-benefit must always be assessed in patients suffering from Primary Immune Thrombocytopenia.
Descripción
La Trombocitopenia Inmune Primaria es una enfermedad hematológica autoinmune que se distingue por tener plaquetas en un número inferior a 100.000, el cual provoca en los pacientes manifestaciones clínicas como la presencia de equimosis, petequias hasta hemorragias masivas que pueden comprometer la vida del paciente. Para su diagnóstico se realizan otros exámenes complementarios, ya que es una patología en la que no existe una prueba estándar o específica para diagnosticarla, y por ende su diagnóstico se la realiza mediante exclusión; y su tratamiento sea de primera, segunda o tercera línea va a depender del número de plaquetas y de la fase de la enfermedad, sobresaliendo los agonistas de la trombopoyetina por sobre otros fármacos en el manejo de la Trombocitopenia Inmune Primaria crónica o refractaria. Describir el manejo farmacológico de la Trombocitopenia Inmune Primaria mediante la administración de los agonistas de la trombopoyetina es fundamental, ya que mediante la misma se lograra evidenciar todos los pacientes que se benefician de este fármaco asi como también su eficacia y la aparición de efectos adversos. Se espera encontrar que los agonistas de la trombopoyetina son fármacos eficaces y seguros en el tratamiento de la Trombocitopenia Inmune Primaria, aunque al ser un tratamiento farmacológico seguro, siempre se debe valorar el riesgo-beneficio en pacientes que padecen Trombocitopenia Inmune Primaria.
Palabras clave
AGONISTA, INMUNE, TROMBOCITOPENIA, TROMBOPOYETINA
Citación
Peña Cordero BE, Reibán Espinoza EA. Agonistas de la trombopoyetina como manejo farmacológico de la trombocitopenia inmune primaria. revistavive [Internet]. 8 de mayo de 2023 [citado 8 de abril de 2024];6(17):647-62. Disponible en: https://revistavive.org/index.php/revistavive/article/view/355